TCF4 and glioblastoma: Although containing β‐catenin‐binding capacity in hyperactive β‐catenin cancer cells, TCF4N has demonstrated to be a β‐catenin‐TCF4 independent regulator in GBM, which neither binds β‐catenin nor alters its cellular distribution and activation.